Beyond SSRIs: New Targets, Psychedelics, and Real-World Decisions in MDD

Psychedelic-assisted therapies are reshaping conversations around the treatment of major depressive disorder and represent one of the most rapidly evolving areas in psychiatry. This session explores the science behind psychedelics alongside other emerging therapeutic targets, reviewing their mechanisms of action, current evidence, and potential role in future clinical practice. Learners will gain practical strategies for evaluating these novel therapies and applying emerging evidence to patient care.